Shares of Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) fell 8.5% on Thursday . The stock traded as low as $1.21 and last traded at $1.29. 576,100 shares were traded during trading, an increase of 103% from the average session volume of 283,985 shares. The stock had previously closed at $1.41.
The firm’s 50 day moving average is $1.38 and its 200 day moving average is $1.55. The firm has a market cap of $19.86 million, a price-to-earnings ratio of 11.83 and a beta of 3.51.
Eleven Biotherapeutics (NASDAQ:EBIO) last released its quarterly earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.30) EPS for the quarter. Eleven Biotherapeutics had a return on equity of 4.26% and a net margin of 11.28%. Equities research analysts anticipate that Eleven Biotherapeutics, Inc. will post ($1.75) earnings per share for the current year.
A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in Eleven Biotherapeutics by 17.4% during the second quarter. Vanguard Group Inc. now owns 206,450 shares of the biopharmaceutical company’s stock worth $324,000 after buying an additional 30,600 shares in the last quarter. Virtu KCG Holdings LLC acquired a new stake in Eleven Biotherapeutics during the second quarter worth about $175,000. Finally, Spark Investment Management LLC acquired a new stake in Eleven Biotherapeutics during the second quarter worth about $148,000. Hedge funds and other institutional investors own 5.05% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/2956091/eleven-biotherapeutics-inc-ebio-trading-down-8-5.html.
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.
Receive News & Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.